1	RetroTest unravels LINE-1 retrotransposition in
2	Head and Neck Squamous Cell Carcinoma
3	
4	Jenifer Brea-Iglesias ^{1,2,3#} , Ana Oitabén ^{1,2,3#} , Sonia Zumalave ² , Bernardo Rodriguez-
5	Martin ^{2,4} , María Gallardo-Gómez ¹ , Martín Santamarina ² , Ana Pequeño-Valtierra ² ,
6	Laura Juaneda-Magdalena ¹ , Ramón García-Escudero ⁵ , José Luis López-Cedrún ⁶ ,
7	Máximo Fraga ⁷ , José MC Tubio ² , Mónica Martínez-Fernández ^{*1,2}
8	#Equal contribution
9	
10	1. Translational Oncology Research Group; Galicia Sur Health Research Institute
11	(IIS Galicia Sur). SERGAS-UVIGO. Estrada de Clara Campoamor, 341, 36213 Vigo,
12	(Spain).
13	2. Mobile Genomes Lab. Centre for Research in Molecular Medicine and Chronic
14	Diseases (CiMUS). (Universidad de Santiago de Compostela). Avda. Barcelona 31,
15	15706 Santiago de Compostela (Spain).
16	3. Equal contribution.
17	4. Present address: Centre for Genomic Regulation (CRG), The Barcelona Institute
18	of Science and Technology, Barcelona (Spain). Universitat Pompeu Fabra (UPF),
19	Barcelona (Spain).
20	5. Molecular and Translational Oncology Division, CIEMAT (ed 70A), Ave
21	Complutense 40, 28040 Madrid (Spain). Research Institute Hospital 12 de Octubre
22	(imas12), 28041 Madrid (Spain). Centro de Investigación Biomédica en Red de
23	Cáncer (CIBERONC), Madrid (Spain).
24	6. Department of Maxillofacial Surgery, University Hospital of A Coruña, As Xubias,
25	84, 15006 A Coruña (Spain).

- 26 7. Pathological Anatomy. Faculty of Medicine. University Clinical Hospital & Health
- 27 Research Institute of Santiago de Compostela (IDIS). Travesa da Choupana s/n,
- 28 15706 Santiago de Compostela (Spain).
- 29
- 30*Correspondingauthor:MonicaMartínezFernández.31monica.martinez@iisgaliciasur.esTranslationalOncology.GaliciaSurHealth32Research Institute (IIS Galicia Sur).Hospital ÁlvaroCunqueiro.Estrada de Clara33Campoamor, 341, 36213 Vigo, (Spain).34
- 35

36 Highlights

37

38	٠	RetroTest	represents	the	first	method	to	determine	LINE-1
39		retrotransp	osition from t	umor	biopsie	s in real cli	nical	settings.	

- RetroTest not only offers global LINE-1 retrotransposition ratios but also
 identifies the active LINE-1 source elements.
- RetroTest elucidates a really early LINE-1 activation in early tumor stages
 of Head and Neck Squamous Cell Carcinoma.
- Whole Genome Analysis and LINE-1 retrotransposition demonstrates
 processes of field cancerization in Head and Neck Squamous Cell
 Carcinoma.
- 47 LINE-1 retrotransposition favors an earlier and more efficient Head and
 48 Neck Squamous Cell Carcinoma diagnosis.
- 49

50 Abstract

51 The relevant role of LINE-1 (L1) retrotransposition in cancer has been recurrently 52 demonstrated in recent years. However, their repetitive nature hampers their 53 identification and detection, hence remaining inaccessible for clinical practice. 54 Also, its clinical relevance for cancer patients is still limited. Here, we develop a 55 new method to quantify L1 activation, called RetroTest, based on targeted 56 sequencing and a sophisticated bioinformatic pipeline, allowing its application in 57 tumor biopsies. First, we performed the benchmarking of the method and 58 confirmed its high specificity and reliability. Then, we unravel the L1 activation in 59 HNSCC according to a more extensive cohort including all the HNSCC tumor stages. Our results confirm that RetroTest is remarkably efficient for L1 detection in 60 61 tumor biopsies, reaching a high sensitivity and specificity. In addition, L1 62 retrotransposition estimation reveals a surprisingly early activation in HNSCC 63 progression, contrary to its classical association with advanced tumor stages. This 64 early activation together with the genomic mutational profiling of normal adjacent

- 65 tissues supports field cancerization process in this tumor. These results underline
- 66 the importance of estimating L1 retrotransposition in clinical practice towards an
- 67 earlier and more efficient diagnosis in HNSCC.
- 68
- 69 Keywords
- 70 Retrotransposition, LINE-1, HNSCC, early diagnosis biomarker, field cancerization

71 **1. Introduction**

72 Approximately half of human genome is composed of transposable elements (TEs). 73 sequences with the ability of moving from one place to another, changing the 74 normal structure of the genome in the places where they are integrated [1,2]. 75 Among them, long interspersed nuclear element retrotransposons (LINE-1, L1) 76 represent 17% of the entire DNA content with approximately 500,000 copies, most 77 of them truncated or inactive [3-6]. Specifically, only a small subset of these L1s is 78 active in the human genome, although they stay transcriptionally repressed due to 79 epigenetic mechanisms that prevent the damage that their mobilization would 80 cause [7]. When this repression is lost, L1 activation can cause different diseases, 81 including cancer [8, 9].

In the framework of the International Consortium of PanCancer (PCAWG), our previous analyses shown that somatic L1 insertions represent the major restructuring source of cancer genomes, especially important for head-and-neck squamous cell carcinoma (HNSCC)[9]. Aberrant L1 retrotransposition contribute to instability within cancer genomes, promoting cancer-driving rearrangements that involve the loss of tumor-suppressor genes and/or the amplification of oncogenes, and favoring some cancer clones to survive and grow [9].

B9 Despite this demonstrated impact of L1 activation in cancer genomes, the 90 repetitive nature of L1 elements and their dispersion along the genome hinder 91 their real activation estimates in tumor samples, preventing its translation into 92 patient diagnosis/prognosis. This repetitive nature compels that the majority of 93 the available detection methods are based on Whole Genome Sequencing (WGS), 94 unfeasible for most hospitals in their diary practice, or require such good quality

95 DNA input quantities that remain unaffordable for a clinical practice mainly based96 on small and degraded tissue biopsies.

97 HNSCC represents the second tumor type with highest L1 activation [9], but the 98 clinical implications of L1 retrotransposition are still to be elucidated. Head and 99 Neck Cancer is a heterogeneous group of cancers of which more than 90% are 100 diagnosed as HNSCC, arising in the stratified epithelium of the oral cavity, pharynx, 101 and larynx [10,11]. Tumor development is often triggered by chronic exposure to 102 tobacco or alcohol, while infection with high-risk human papillomaviruses (HPVs) 103 causes a substantial and rising proportion of these tumors [12]. The lack of 104 symptoms in the early stages together with the non-existent cancer biomarkers 105 lead towards most diagnoses at advanced stages, where the 5-year survival rate is 106 less than 50% [11]. Thus, there is an urgent need to find molecular biomarkers 107 that can facilitate an earlier diagnosis and increase patients' life expectancy.

108 Based on this, we aimed to unravel the impact of possible L1 activation along 109 HNSCC development in a clinical setting. First, we have developed a new efficient 110 method based on L1 transductions, RetroTest, to measure L1 activation even in 111 biopsies with low DNA inputs. Then, we have evaluated RetroTest sensitivity and 112 specificity, demonstrating its high values. Finally, we have assessed L1 113 retrotransposition along different tumor stages, unraveling for the fist time a really 114 early activation in HNSCC and field characterization, arising L1 as a promising 115 early diagnostic biomarker.

116

118 **2. Materials and methods**

119 *2.1. Patients and tumor samples*

120 Tumor samples and medical records were analyzed in a series of 96 HNSCC patients of 3 different cohorts (Complexo Hospitalario Universitario de A Coruña 121 122 (CHUAC), Biobanco Vasco and Fundación Pública Galega de Medicina Xenómica 123 (FPGMX)). The Ethical Committee for Clinical Research of Santiago-Lugo approved 124 the study (CEIC 2018/567). Fresh-frozen and FFPE HNSCC tissue biopsies were 125 collected, and characteristics of each tumor are specified in Table 1. The 126 histopathologic status was confirmed by each corresponding Pathology 127 Department following the latest TNM guidelines.

128

129 2.2. DNA isolation

Genomic DNA (gDNA) was extracted from fresh-frozen tissue and formalin-fixed
paraffin-embedded (FFPE) samples using AllPrep DNA/RNA and AllPrep FFPE
DNA/RNA Mini Kits (Qiagen), respectively. DNA quantification and integrity were
assessed using Qubit dsDNA BR Assay Kit in Qubit 4.0 (ThermoFisher Scientific)
and a 4200 TapeStation system (Agilent).

135

136 2.3. RetroTest method: design, library construction and target sequencing

During L1 transcription, the processing machinery sometimes bypasses the L1 polyadenylation signal until a second 3' downstream polyadenylation site, mobilizing unique sequences downstream of the element in a process called *L1 3' transduction*. This process has been reported to occur in around 10% of the L1 mobilizations [7] and can be used as an indirect measurement of real active L1 elements. Accordingly, there are three different types of retrotranspositions: solo-

143 L1 (TD0), when a partial or complete L1 is retrotransposed; partnered 144 transductions (TD1), in which a L1 and downstream unique sequence are 145 retrotransposed; and orphan transductions (TD2), in which only the unique 146 sequence downstream of the active L1 is mobilized without the associated L1 [7]. 147 RetroTest is based on targeted sequencing, where the capture probes are designed 148 against the unique sequence downstream of the 124 L1 full-length competent 149 elements previously described [7] using SureSelect design from Agilent. RetroTest 150 identifies L1 TD2 orphan insertions through the detection of discordant reads and 151 clipped reads. The main idea behind the method is that discordant read pairs, 152 where one of the mates is mapped to a L1 3' downstream sequence while the other 153 is mapped to the insertion target sequence, support an insertion. In addition, 154 clipped reads, mapped to the target sequence but containing a discordant extreme 155 blatting to a L1 3' downstream sequence, are detected to identify the breakpoint of 156 the insertion (Fig. 1A). Here, a minimum size of 2 reads per cluster and a minimum 157 of 4 supporting reads was specified to call a L1 insertion (Additional file 1).

Target libraries were constructed with SureSelect Target Enrichment System for Illumina Paired-End Multiplexed Sequencing (Agilent). 100 ng of gDNA from each sample were sheared using a Covaris M220 Focused-Ultrasonicator (Covaris) and libraries and capture with targeted RNA baits were performed. The multiplexed samples were sequenced with Illumina 150bp paired-end.

Sequencing reads were mapped to the hg19 reference genome by Burrows-Wheeler Aligner BWA-mem [13]. Samtools [14] was used to sort the aligned reads and to index the obtained bam file, applying Bammarkduplicates2 from Picard tools [15] to mark duplicated reads.

167

168 2.4. RetroTest benchmarking

We generated simulated paired-end read datasets using ART [16] and several
commands from MEIGA-MEIsimulator, an in-house bioinformatic tool (Additional
file 1).

172 To mimic the capture process, we selected read pairs with at least one of the mates 173 mapping on a given set of target regions with Picard FilterSamReads v2.18.14 [15]. 174 We used the resulting bam files to assess sensitivity and specificity under different 175 conditions. To test how our method performs with subclonal events, we simulated 176 transductions at different VAFs (10%, 20%, 40% and 50%). We also studied how coverage affects the detection power of our algorithm. Using Picard 177 178 DownSampleSam v2.18.14 [15], we subsampled reads from a 150x simulation at 179 50% VAF under different sequencing depths (15x, 30x, 60x, 90x, 120x and 150x).

180 We compared RetroTest performance with Transposon Finder in Cancer (TraFiC), 181 used previously to explore somatic retrotransposition in PCAWG [7]. Both were 182 used to call the simulated events. Precision was calculated dividing the number of 183 true positive calls by the number of total calls performed by the method. Recall 184 was calculated dividing the number of true positive calls by the number of total 185 simulated events. True positives, False positives and False negatives were 186 identified by intersecting the coordinates of simulated events with the coordinates 187 of the calls using BEDTools intersect [17]. To compare RetroTest and TraFiC results, Venn diagrams with the insertions detected by each method were plotted 188 189 by using *vennDiagram* R package.

190

191 2. 5. Whole Genome Sequencing and determination of mutation profile.

To obtain WGS data, DNA was sent to an external service (Macrogen). Truseq Nano
DNA Libraries (350bp) were constructed and sequenced in a NovaSeq6000
Illumina platform (150bp paired-end). For a detailed explanation see Additional
File 1.

196

197 2.6. Statistical analyses

The association between L1 transduction rate (corrected by coverage) and patient clinical features was assessed by multiple linear regressions. Wilcoxon or Fisher test, depending on sample size, were applied to compare the differences in mean values for clinical variables. Overall survival (OS), progression free survival (PFS) and survival probability analyses were performed with the *survminer* and *survival* R packages, using log-rank test to compare different groups. The association between survival and clinical variables was evaluated by Cox regression.

205

206 2.7. Enrichment analysis

All enrichment analyses were performed using *enrichR* R package [18]. The
complete list of pathways databases can be found in Additional File 1.

209

211 **3. Results**

212 3.1. RetroTest Benchmarking

213 During L1 transcription, transductions are reported to occur in around 10% of the 214 L1 mobilizations [7], moving also unique sequences downstream of the source 215 element. RetroTest is designed to capture these mobilized and downstream-216 transduced unique sequences from orphan transductions (TD2) and use them as 217 barcodes (Fig. 1A). These barcodes can identify unequivocally the insertions 218 caused by these 124 L1 source elements active in cancer [7,9]. With this aim, we 219 focused RetroTest probe design on the first 5000 nucleotides adjacent to the L1 3' 220 regions for each of the 124 L1 source elements, since these are the regions most 221 frequently transduced [7]. Since RetroTest uses transductions as an indirect 222 measure of real L1 activation, we first compared L1 activation versus TD2 using the 223 whole PCAWG data. In this way, we confirmed a high and statistically significant 224 correlation between both events (r=0.88, $p=2.2e^{-16}$), and a relation of 1:10 as 225 previously described (Fig. 1B).

226 Next, we optimized the lab protocol for both FFPE and fresh-frozen tissues and 227 developed an associated bioinformatic pipeline. We evaluated the performance 228 and accuracy of RetroTest in detecting L1 activation by generating an artificial 229 cancer genome. In this genome, we have randomly distributed a total of 2480 L1 230 transductions. Using simulations, we assessed the performance of RetroTest for 231 different sequencing depth: 15x, 30x, 60x, 90x, 120x and 150x. RetroTest obtained 232 a precision around 0.99 in all cases and a recall around 0.96 (Fig. 1C). We also 233 evaluated the variation of the performance depending on the variant allele 234 frequency (VAF) of the integrations, precisely for the following VAFs: 10%, 20%, 235 40% and 50%. In this case, RetroTest obtained a precision around 1, decreasing

for lower VAFs, and a recall ranged from 0.81 to 0.96, augmenting as increasing the
VAF (Fig. 1D).

238 Then, we compared RetroTest and the classical TraFiC, used for WGS in PCAWG 239 [7]. As TraFiC is designed to work only with standard WGS 30x data, we compared 240 the analysis varying exclusively the VAFs. TraFiC precision ranged from 0.99 to 241 0.88 and recall ranged from 0.11 to 0.87 as VAF increased (although the maximum 242 recall was obtained for VAFs of 40%, being 0.87) (Fig. 1E) (Additional File 2: Table 243 S1). We compared the performance of both methods by intersecting both calls in 244 the mock tumor genome. Using a VAF of 50%, most of the variants were called by 245 both methods, concretely 2216 variants, while RetroTest exclusively called 167, 246 and TraFiC 33 private events, most of them resulting in false positives according to 247 IGV (Fig. 1F).

248

249 *3.2. L1 activation in HNSCC*

250 Once confirmed the accuracy and precision of RetroTest, we decided to apply it to 251 a more extensive HNSCC cohort, composed of 96 tumors along the tumor stages, 252 from T1 to T4 (Table 1). We detected L1 activation in 75% of the patients (Fig. 2A), 253 out of which 48.6% showed high activity (beyond the median) (Table 2). When the 254 activation was studied along the different tumor stages of the disease, advanced 255 disease (T3-T4) showed statistically higher L1 activation compared with early stages (T1-T2) (p=0.0072) (Fig. 2B). Following tumor staging, L1 activation was 256 detected in 62.5% of T1 tumors, 63.1% of T2 tumors, 94.4% of T3 tumors, and 257 258 73.5% of the tumors in T4 (Table 2). The detection of L1 activation in all the tumor 259 stages among the different patients, even in the first stage of the disease (T1), 260 supports an early L1 activation during tumor progression.

Then, we analyzed L1 activation considering different patients' clinical 261 262 characteristics, finding no statistically significant association between the L1 263 activation and alcohol consumption (p=0.14) or sex (p=0.055). Interestingly, 264 smoker patients showed statistically significantly higher L1 activity than non-265 smokers (p=0.0015) (Fig. 2C). We did not find an association between L1 266 activation and survival probability (p=0.59 active vs. inactive, p=0.49 high vs. low 267 rate) (Additional File 3: Fig. S1), although when considering those T1 patients who 268 have L1 already active at early stages, Kaplan-Meier curve showed that they tend 269 to have a lower survival probability, not being statistically significant (p=0.43)270 (Fig. 2D).

Finally, in addition to localizing the position of each transduction, RetroTest can also identify the source L1 element that has been mobilized. Thus, we have detected L1 transductions in 23 genes throughout 27 patients. As shown in Fig. 2E, most of these insertions are caused by a few source elements that resulted very active in HNSCC, especially the 22q12.1.

276

277 3.3. HNSCC mutation profile and L1 activation

278 To further characterize the molecular profile of L1 activation in our HNSCC cohort, 279 we obtained WGS data from 19 tumor samples from patients measured by 280 RetroTest. To detect only somatic variation, their corresponding paired-normal 281 samples were included as germline control. We detected a median of 40 single 282 nucleotide variants (SNVs) and INDELs, identifying a total of 1012 somatic variants 283 throughout the cohort, affecting 918 genes (Additional File 2: Table S2). As shown 284 in Fig. 3A, we did not detect a correlation between L1 activation and the general 285 tumor mutation burden (TMB). Our results showed that the most frequently

mutated gene was TP53 (36.8%), followed by NOTCH1 (26.3%), MT-ND5 (26.3%), 286 287 FAT1, and GRIN2A (21.1%). Interestingly, we found that most of the patients with 288 TP53 mutations showed also high L1 activity (71.4%). In fact, when we compared 289 the L1 activation with the *TP53* mutation, we found a clear association (p=0.056) 290 (Fig. 3B). Enrichment analyses with the mutated genes showed involved key 291 processes for cancer progression such as Notch signaling, TGFß signaling, and 292 again *p53 activity regulation* (Fig. 3C) (Additional File 2: Table S3). CHEA analysis 293 revealed the alteration of transcription factors related to epigenetic mechanisms 294 including Polycomb members (EZH2, SUZ12) (Fig. 3D) (Additional File 2: Table S4). 295

296 *3.4. Profiling normal adjacent tissues to the HNSCC tumor (NAT)*

297 To further understand the early HNSCC features, we decided to evaluate a possible 298 field cancerization process, in which the normal cell population is replaced by 299 cancer-primed cells, without anatomical or morphological changes, but being 300 already premalignant at molecular level. To this, we analyzed the available normal 301 samples obtained from adjacent tissues to the tumor and the peripheral blood 302 mononuclear cells (PBMCs), used as germline control (Fig. 4A). We detected a total 303 of 25 high impact and/or possibly pathogenic somatic variants affecting the NAT 304 (Additional File 2: Table S5). Most of these specific mutations (n=20; 80%) were 305 exclusive from NAT tissue, including those affecting key genes such as NOTCH1 306 (the most mutated gene), FAT1 or PPARD; while 20% were shared between NAT 307 and tumor tissue, affecting genes such as *CDKN2A*.

308 To elucidate whether L1 further supports field cancerization, we evaluated the 309 NAT of a total of 9 patients by RetroTest. We compared the L1 elements active in 310 the tumor, in the NAT, and in their corresponding paired germline. In this way, we

could confirm that most of the L1 activation was present only in the tumor, 5
insertions resulted germline, and 1 element appeared active and shared by tumor
and NAT. Surprisingly, 4 insertions appeared exclusively in NAT (Fig. 4B). Thus, we
could confirm field cancerization and demonstrate that L1 is already active in NAT,
supporting once again its early activation in HNSCC.

316

317 4. Discussion

318 Since the recently demonstrated high impact of L1 in cancer genomes [7,9], L1 has 319 been evaluated as a cancer biomarker in different studies assessing its activity by 320 evaluating L1 methylation, RNA expression, or protein levels [19-22]. However, 321 most of L1 genome sequences are truncated and not functional, so results can 322 present important biases in their L1 estimations, while its translation into clinical 323 routine can be challenging due to RNA/protein instability. Previous proposed 324 technologies based on DNA full-length L1 retrotransposon capture sequencing, 325 such as RC-seq [23], present the associated possible bias of the real L1 activation, 326 besides only offer global L1 estimates, and important DNA requirements $(2.5 \mu g$ 327 starting genomic DNA), unaffordable for clinical practice. The most recent 328 approaches are based on the identification of L1 insertions as real L1 activation 329 measure (TraFiC [7], xTea [24], MELT [25] and Mobster [26]). They use Whole 330 Genome or Whole Exome Sequencing from Illumina pair-end short reads, 331 nevertheless, short reads hamper the detection of transposable elements 332 insertions in highly repetitive or complex rearrangement regions. Additionally, 333 these high throughput approaches are not affordable for most of the hospitals. 334 More recently, long reads sequencing has arisen as a new possibility (xTea [24], 335 PALMER [27]), but again their requirements of huge amounts of high-quality DNA

336 remain unaffordable for biopsies mainly composed of small samples and 337 fragmented DNA. Thus, incorporating L1 activation into the clinical practice 338 requires new methods supported by standardization and rigorous validation to 339 demonstrate its utility.

340 Here, we present RetroTest: a new method to detect real L1 activation in clinical 341 samples with low DNA input requirements, both from fresh/frozen or FFPE 342 biopsies. Its novelty and power lie in the targeted detection of active source L1 343 elements, which showed a highly and direct statistical correlation with total L1 344 activity (as demonstrated by our data) in a more cost-effective than previously 345 proposed approaches. Our method not only offers global L1 estimates but also 346 identifies the L1 elements active in each real sample. Our benchmarking supports 347 the high precision (1) and recall of RetroTest (0.81-0.96), improving according to 348 coverage, even reaching the possibility of detecting subclonal insertions. The high 349 coincidence in the variants called by TraFic and RetroTest, in both simulations and 350 real-world data, supports the high potential for this new methodology.

351 L1 somatic retrotransposition was previously demonstrated as the second most 352 frequent type of structural variants among HNSCC genomes [9]. Accordingly, our 353 results demonstrate that most HNSCC patients (75%) present L1 activation, even 354 near half of them with high levels (49%). The activation was higher in late stages, 355 as found in Barret's esophagus, where lower L1 activity was detected in the early 356 stages increasing with cancer progression [28]. Interestingly, we found a 357 surprisingly early activation already in the first stages of HNSCC, with activation of 358 L1 in 62-63% of the T1 patients. These data pointed towards L1 activation as an 359 early event in the configuration of HNSCC genomes and, thus, in the development

of the disease. In fact, those stage T1 patients with L1 activation tended to presenta lower OS.

362 We found an association between high L1 activity and smoking habits. Previous 363 studies had reported higher hypomethylation rates of L1 in smokers [29], even in 364 non-cancerous epithelial tissues [30]. Considering that around 75% of HNSCC are 365 associated with tobacco [31], this mechanism could be responsible for the high L1 366 activity levels in HNSCC, since methylation is one of the best-demonstrated 367 mechanisms preventing L1 reactivation [7,32]. In fact, L1 hypomethylation has 368 been associated with worse prognosis in HNSCC, including a higher risk of relapse 369 [33-35]. This hypomethylation has been found as an early event in CRC, gastric 370 and oral cancer [36-39]. Interestingly, it was reported that L1 methylation levels 371 were significantly lower in oral premalignant lesions of patients who then 372 developed oral cancer [39].

The source element L1 most active in our cohort was that at 22q12.1, coincident with our previous results [7, 10]. This L1 is located antisense to an intron of the TTC28 gene and has been also recently identified as the intact LINE-1 mRNA most highly expressed in breast, ovarian and colon cancer [40], and the L1 element accounting for most transductions in colorrectal cancer [33], supporting the same hottest activity in HNSCC.

Our WGS analyses confirmed no correlation between L1 activity and TMB, but an association between *TP53* mutation and L1 activation, in line with previous studies suggesting that *TP53* can repress L1 mobilization [9,40–43]. We also identified an important epigenetic regulation among the transcription factors strongly interacting with the mutated genes, specially related to repressive complex Polycomb. Intriguingly, Mangoni et al. have just deciphered that L1 RNAs can act as

long non-coding RNAs and directly interact with the Polycomb during brain development and evolution [44]. We also reported previously that Polycomb could regulate lncRNA *HOTAIR* in bladder cancer [45]. In the same sense, Ishak et al. demonstrated an EZH2-dependent silencing of genomic repeat sequences, including L1 elements [46]. Therefore, additional analyses would be required to further address if this epigenetic network plays a role in cancer genome reorganization.

392 Then, to evaluate possible HNSCC early diagnosis potential biomarkers is 393 fundamental to get insights into the transition from pre-tumoral to cancer disease. 394 Thus, we evaluated the presence of field cancerization and identified genetic 395 features that can eventually lead to cancer development [47], finding exclusive 396 somatic mutations in the NAT and a small proportion shared with the tumor. 397 Several studies have recently described patchworks of different clones in normal 398 tissues, some of them even bearing driver mutations, increasing with age or 399 smoking habits [48-50]. We found NOTCH1 and FAT1 as the most mutated genes, 400 as Martincorena's results in normal skin and esophagus [48,51]. These genes 401 showed also high mutation rates in the tumor, indicating the presence of a 402 precancerous or cancer invasion field.

Finally, when we evaluated L1 activity, several mobilizations were exclusively found in NAT, and only one appeared shared with the tumor, again supporting a cancerization field. Somatic L1 retrotransposition events have been recently described in normal urothelium and colorectal epithelium, although with much lower rates than in bladder and colorectal cancer [52,53]. L1 activity has been also described in a few pre-tumor samples including Barrett's esophagus and colorectal adenomas [8,28,54]. Therefore, L1 activation arises as a reinforced early event,

even in pre-tumor stages, in the natural history of HNSCC, with the associatedpotential of L1 as a field cancerization biomarker.

412

413 **Conclusions**

We present the development and benchmarking of RetroTest, which allows an easy measurement of real L1 activation from small tumor biopsies with high efficacy, favoring its implementation in real clinical settings. RetroTest revealed that most of the HNSCC patients present L1 activation, associated with smoking habits and already active in early stages of the disease and NAT, supporting a field cancerization process and its potential as early diagnostic biomarker.

420

421 Acknowledgements

422 Authors thank all the enrolled patients and their families. This research project 423 was made possible through the access granted by the Galician Supercomputing 424 Center (CESGA) to its supercomputing infrastructure. The supercomputer 425 FinisTerrae III and its permanent data storage system have been funded by the 426 Spanish Ministry of Science and Innovation, the Galician Government and the 427 European Regional Development Fund (ERDF).

This work was supported by the Instituto de Salud Carlos III (ISCIII) and the European Social Fund ("Investing in your future") (PI19/01113, and partially by P121/00208, co-funded by FEDER and the European Union), and the Spanish Association Against Cancer Scientific Foundation (IDEAS19122MART). A.O. was supported by a predoctoral fellowship from the Galician Innovation Agency, Xunta de Galicia (ED481A-2020/214). M.M.-F. and J.B. were previously supported by the Spanish Association Against Cancer Scientific Foundation (INVES207MART and

435	PRDCR19007BREA_001, respectively). M.MF. is currently supported by the
436	Miguel Servet program (CP20/00188) from the Instituto de Salud Carlos III (ISCIII)
437	and the European Social Fund ("Investing in your future"). M.G-G. is supported by a
438	postdoctoral fellowship from the Galician Innovation Agency, Xunta de Galicia
439	(IN606B-2024/014).
440	
441	Ethics statement
442	The Ethical Committee for Clinical Research of Santiago-Lugo gave ethical approval
443	for this work (CEIC 2018/567).
444	
445	Competing interests
446	The authors declare no competing interests.
447	
448	Consent for publication
449	All authors give consent for the publication of this manuscript.
450	
451	Data availability statement

- 452 Whole Genome Sequencing data from the HNSCC cohort is deposited into the
- 453 Sequence Read Archive (SRA) repository under the following BioProject ID:
- 454 PRJNA1053897. RetroTest pipeline is publicly available at
- 455 <u>https://gitlab.com/mobilegenomesgroup/RETROTEST</u>.
- 456

457 **CRediT authorship contribution statement**

458 Jenifer Brea-Iglesias and Ana Oitabén: Conceptualization, Methodology,
459 Software, Data curation, Investigation, Validation, Visualization, Writing – review

460 and editing. **Sonia Zumalave**: Conceptualization. Investigation. Methodology. 461 Software, Validation, Writing – review and editing. Bernardo Rodríguez-Martin: 462 Conceptualization, Methodology, Software. María Gallardo-Gómez: 463 Conceptualization, Visualization, Writing - review and editing. Martin 464 Santamarina: Methodology. Validation. Ana **Pequeño-Valtierra**: 465 Conceptualization, Investigation. Laura Juaneda-Magdalena: Methodology, 466 Conceptualization, Writing - review and editing. Ramón García-Escudero: 467 Methodology, Writing - review and editing. Jose Luis López-Cedrún: 468 Methodology. Máximo Fraga: Funding acquisition. José MC Tubio: 469 Conceptualization, Funding acquisition. Mónica Martínez-Fernández: Writing -470 review & editing, Writing – original draft, Supervision, Resources, Investigation, 471 Project administration, Funding acquisition, Conceptualization, All authors 472 approved the final version.

473

474 **References**

- 475 [1] H.H. Kazazian, J. V. Moran, The impact of L1 retrotransposons on the human
 476 genome, Nat. Genet. 19 (1998) 19–24. https://doi.org/10.1038/NG0598-19.
- 477 [2] E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K.

478 Devon, K. Dewar, M. Doyle, W. Fitzhugh, R. Funke, D. Gage, K. Harris, A.

479 Heaford, J. Howland, L. Kann, J. Lehoczky, R. Levine, P. McEwan, K.

- 480 McKernan, J. Meldrim, J.P. Mesirov, C. Miranda, W. Morris, J. Naylor, C.
- 481 Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, N. Stange-Thomann,
- 482 N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough,
- 483 S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P.
- 484 Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S.

485	Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray,
486	L. Matthews, S. Mercer, S. Milne, J.C. Mullikin, A. Mungall, R. Plumb, M. Ross,
487	R. Shownkeen, S. Sims, R.H. Waterston, R.K. Wilson, L.W. Hillier, J.D.
488	McPherson, M.A. Marra, E.R. Mardis, L.A. Fulton, A.T. Chinwalla, K.H. Pepin,
489	W.R. Gish, S.L. Chissoe, M.C. Wendl, K.D. Delehaunty, T.L. Miner, A.
490	Delehaunty, J.B. Kramer, L.L. Cook, R.S. Fulton, D.L. Johnson, P.J. Minx, S.W.
491	Clifton, T. Hawkins, E. Branscomb, P. Predki, P. Richardson, S. Wenning, T.
492	Slezak, N. Doggett, J.F. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M.
493	Frazier, R.A. Gibbs, D.M. Muzny, S.E. Scherer, J.B. Bouck, E.J. Sodergren, K.C.
494	Worley, C.M. Rives, J.H. Gorrell, M.L. Metzker, S.L. Naylor, R.S. Kucherlapati,
495	D.L. Nelson, G.M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, T. Yada, A.
496	Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J.
497	Weissenbach, R. Heilig, W. Saurin, F. Artiguenave, P. Brottier, T. Bruls, E.
498	Pelletier, C. Robert, P. Wincker, A. Rosenthal, M. Platzer, G. Nyakatura, S.
499	Taudien, A. Rump, D.R. Smith, L. Doucette-Stamm, M. Rubenfield, K.
500	Weinstock, M.L. Hong, J. Dubois, H. Yang, J. Yu, J. Wang, G. Huang, J. Gu, L.
501	Hood, L. Rowen, A. Madan, S. Qin, R.W. Davis, N.A. Federspiel, A.P. Abola, M.J.
502	Proctor, B.A. Roe, F. Chen, H. Pan, J. Ramser, H. Lehrach, R. Reinhardt, W.R.
503	McCombie, M. De La Bastide, N. Dedhia, H. Blöcker, K. Hornischer, G.
504	Nordsiek, R. Agarwala, L. Aravind, J.A. Bailey, A. Bateman, S. Batzoglou, E.
505	Birney, P. Bork, D.G. Brown, C.B. Burge, L. Cerutti, H.C. Chen, D. Church, M.
506	Clamp, R.R. Copley, T. Doerks, S.R. Eddy, E.E. Eichler, T.S. Furey, J. Galagan,
507	J.G.R. Gilbert, C. Harmon, Y. Hayashizaki, D. Haussler, H. Hermjakob, K.
508	Hokamp, W. Jang, L.S. Johnson, T.A. Jones, S. Kasif, A. Kaspryzk, S. Kennedy,
509	W.J. Kent, P. Kitts, E. V. Koonin, I. Korf, D. Kulp, D. Lancet, T.M. Lowe, A.

510	McLysaght.	T. Mikkelsen,	I. V. Moran	. N. Mulder, V	VI Pollara	. C.P. Ponting.	G

- 511 Schuler, J. Schultz, G. Slater, A.F.A. Smit, E. Stupka, J. Szustakowki, D. Thierry-
- 512 Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, R. Wheeler, A. Williams, Y.I. Wolf,
- 513 K.H. Wolfe, S.P. Yang, R.F. Yeh, F. Collins, M.S. Guyer, J. Peterson, A.
- 514 Felsenfeld, K.A. Wetterstrand, R.M. Myers, J. Schmutz, M. Dickson, J.
- 515 Grimwood, D.R. Cox, M. V. Olson, R. Kaul, C. Raymond, N. Shimizu, K.
- 516 Kawasaki, S. Minoshima, G.A. Evans, M. Athanasiou, R. Schultz, A. Patrinos,
- 517 M.J. Morgan, Initial sequencing and analysis of the human genome, Nature
- 518 409 (2001) 860–921. https://doi.org/10.1038/35057062.
- 519 [3] C.R. Beck, P. Collier, C. Macfarlane, M. Malig, J.M. Kidd, E.E. Eichler, R.M.
- 520 Badge, J. V. Moran, LINE-1 retrotransposition activity in human genomes,
- 521 Cell 141 (2010) 1159–1170.
- 522 [4] B. Brouha, J. Schustak, R.M. Badge, S. Lutz-Prigge, A.H. Farley, J. V. Morant,
- 523 H.H. Kazazian, Hot L1s account for the bulk of retrotransposition in the
- 524 human population, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5280–5285.
- 525 [5] S.J. Hoyt, J.M. Storer, G.A. Hartley, P.G.S. Grady, A. Gershman, L.G. de Lima, C.
- 526 Limouse, R. Halabian, L. Wojenski, M. Rodriguez, N. Altemose, A. Rhie, L.J.
- 527 Core, J.L. Gerton, W. Makalowski, D. Olson, J. Rosen, A.F.A. Smit, A.F. Straight,
- 528 M.R. Vollger, T.J. Wheeler, M.C. Schatz, E.E. Eichler, A.M. Phillippy, W. Timp,
- 529 K.H. Miga, R.J. O'Neill, From telomere to telomere: The transcriptional and
- 530 epigenetic state of human repeat elements, Science. 376 (2022).
- 531 https://doi.org/10.1126/science.abk3112.
- 532 [6] D.M. Sassaman, B.A. Dombroski, J. V. Moran, M.L. Kimberland, T.P. Naas, R.J.
- 533 DeBerardinis, A. Gabriel, G.D. Swergold, H.H. Kazazian, Many human L1
- elements are capable of retrotransposition, Nat. Genet. 16 (1997) 37–43.

- 535 [7] J.M.C. e. al Tubio, Extensive transduction of nonrepetitive DNA mediated by
- 536 L1retrotransposition in cancer genomes, Science. 345 (2014) 1251343.
- 537 https://doi.org/10.1126/science.1251343.Extensive.
- 538 [8] A.D. Ewing, A. Gacita, L.D. Wood, F. Ma, D. Xing, M.S. Kim, S.S. Manda, G. Abril,
- 539 G. Pereira, A. Makohon-Moore, L.H.J. Looijenga, A.J.M. Gillis, R.H. Hruban, R.A.
- 540 Anders, K.E. Romans, A. Pandey, C.A. Iacobuzio-Donahue, B. Vogelstein, K.W.
- 541 Kinzler, H.H. Kazazian, S. Solyom, Widespread somatic L1 retrotransposition
- 542 occurs early during gastrointestinal cancer evolution, Genome Res. 25
- 543 (2015) 1536–1545. https://doi.org/10.1101/gr.196238.115.
- 544 [9] B. Rodriguez-Martin, E.G. Alvarez, A. Baez-Ortega, J. Zamora, F. Supek, J.
- 545 Demeulemeester, M. Santamarina, Y.S. Ju, J. Temes, D. Garcia-Souto, H.
- 546 Detering, Y. Li, J. Rodriguez-Castro, A. Dueso-Barroso, A.L. Bruzos, S.C.
- 547 Dentro, M.G. Blanco, G. Contino, D. Ardeljan, M. Tojo, N.D. Roberts, S.
- 548 Zumalave, P.A.W. Edwards, J. Weischenfeldt, M. Puiggròs, Z. Chong, K. Chen,
- 549 E.A. Lee, J.A. Wala, K. Raine, A. Butler, S.M. Waszak, F.C.P. Navarro, S.E.
- 550 Schumacher, J. Monlong, F. Maura, N. Bolli, G. Bourque, M. Gerstein, P.J. Park,
- 551 D.C. Wedge, R. Beroukhim, D. Torrents, J.O. Korbel, I.I. Martincorena, R.C.
- 552 Fitzgerald, P. Van Loo, H.H. Kazazian, K.H. Burns, K.C. Akdemir, E.G. Alvarez,
- A. Baez-Ortega, R. Beroukhim, P.C. Boutros, D.D.L. Bowtell, B. Brors, K.H.
- 554 Burns, P.J. Campbell, K. Chan, I. Cortés-Ciriano, A. Dueso-Barroso, A.J.
- 555 Dunford, P.A.W. Edwards, X. Estivill, D. Etemadmoghadam, L. Feuerbach, J.L.
- 556 Fink, M. Frenkel-Morgenstern, D.W. Garsed, M. Gerstein, D.A. Gordenin, D.
- 557 Haan, J.E. Haber, J.M. Hess, B. Hutter, M. Imielinski, D.T.W. Jones, M.D.
- 558 Kazanov, L.J. Klimczak, Y. Koh, J.O. Korbel, K. Kumar, E.A. Lee, J.J.K. Lee, Y. Li,
- 559 A.G. Lynch, G. Macintyre, F. Markowetz, A. Martinez-Fundichely, M.

560		Meyerson, S. Miyano, H. Nakagawa, F.C.P. Navarro, S. Ossowski, J. V. Pearson,
561		J. V. Pearson, K. Rippe, N.D. Roberts, S.A. Roberts, B. Rodriguez-Martin, B.
562		Rodriguez-Martin, S.E. Schumacher, M. Shackleton, N. Sidiropoulos, L.
563		Sieverling, C. Stewart, J.M.C. Tubio, I. Villasante, N. Waddell, J.A. Wala, J.
564		Weischenfeldt, L. Yang, X. Yao, S.S. Yoon, J. Zamora, C.Z. Zhang, P.J. Campbell,
565		J.M.C. Tubio, S.E. Schumacher, R. Scully, B. Rodriguez-Martin, Y.S. Ju, M.D.
566		Kazanov, L.J. Klimczak, Y. Koh, J.O. Korbel, K. Kumar, E.A. Lee, J.J.K. Lee, Y. Li,
567		A.G. Lynch, G. Macintyre, F. Markowetz, I.I. Martincorena, A. Martinez-
568		Fundichely, M. Meyerson, S. Miyano, H. Nakagawa, F.C.P. Navarro, S.
569		Ossowski, J. V. Pearson, M. Puiggròs, K. Rippe, N.D. Roberts, S.A. Roberts, B.
570		Rodriguez-Martin, S.E. Schumacher, R. Scully, M. Shackleton, N. Sidiropoulos,
571		L. Sieverling, C. Stewart, J.M.C. Tubio, I. Villasante, N. Waddell, J.A. Wala, J.
572		Weischenfeldt, L. Yang, X. Yao, S.S. Yoon, J. Zamora, C.Z. Zhang, P.J. Campbell,
573		J.M.C. Tubio, Pan-cancer analysis of whole genomes identifies driver
574		rearrangements promoted by LINE-1 retrotransposition, Nat. Genet. 52
575		(2020) 306–319. https://doi.org/10.1038/s41588-019-0562-0.
576	[10]	A. Jou, J. Hess, Epidemiology and Molecular Biology of Head and Neck
577		Cancer, Oncol. Res. Treat. 40 (2017) 328–332.
578		https://doi.org/10.1159/000477127.
579	[11]	M. Plath, J. Gass, M. Hlevnjak, Q. Li, B. Feng, X.P. Hostench, M. Bieg, L.
580		Schroeder, D. Holzinger, M. Zapatka, K. Freier, W. Weichert, J. Hess, K. Zaoui,
581		Unraveling most abundant mutational signatures in head and neck cancer,
582		Int. J. Cancer 148 (2021) 115–127. https://doi.org/10.1002/IJC.33297.
583	[12]	C.R. Leemans, B.J.M. Braakhuis, R.H. Brakenhoff, The molecular biology of
584		head and neck cancer, Nat. Rev. Cancer 11 (2011) 9–22.

585 https://doi.org/10.1038/nrc2982.

- 586 [13] H. Li, Aligning sequence reads, clone sequences and assembly contigs with
- 587 BWA-MEM, ArXiv: Genomics (2013).
- 588 https://doi.org/10.6084/M9.FIGSHARE.963153.V1.
- 589 [14] P. Danecek, J.K. Bonfield, J. Liddle, J. Marshall, V. Ohan, M.O. Pollard, A.
- 590 Whitwham, T. Keane, S.A. McCarthy, R.M. Davies, Twelve years of SAMtools
- and BCFtools, Gigascience 10 (2021) 1–4.
- 592 https://doi.org/10.1093/GIGASCIENCE/GIAB008.
- 593 [15] Broad Institute, Picard Tools, Http://Broadinstitute.Github.Io/Picard/ (n.d.).
- 594 [16] W. Huang, L. Li, J.R. Myers, G.T. Marth, ART: a next-generation sequencing
- read simulator, Bioinformatics 28 (2012) 593–594.
- 596 https://doi.org/10.1093/BIOINFORMATICS/BTR708.
- 597 [17] A.R. Quinlan, I.M. Hall, BEDTools: a flexible suite of utilities for comparing
- genomic features, Bioinformatics 26 (2010) 841–842.
- 599 https://doi.org/10.1093/BIOINFORMATICS/BTQ033.
- 600 [18] M. V. Kuleshov, M.R. Jones, A.D. Rouillard, N.F. Fernandez, Q. Duan, Z. Wang,
- 601 S. Koplev, S.L. Jenkins, K.M. Jagodnik, A. Lachmann, M.G. McDermott, C.D.
- 602 Monteiro, G.W. Gundersen, A. Maayan, Enrichr: a comprehensive gene set
- 603 enrichment analysis web server 2016 update, Nucleic Acids Res. 44 (2016)
- 604 W90–W97. https://doi.org/10.1093/NAR/GKW377.
- 605 [19] D. Ardeljan, M.S. Taylor, D.T. Ting, K.H. Burns, The Human Long Interspersed
- 606 Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia, Clin.
- 607 Chem. 63 (2017) 816–822.
- 608 https://doi.org/10.1373/CLINCHEM.2016.257444.
- 609 [20] M.L. Filipenko, U.A. Boyarskikh, L.S. Leskov, K. V. Subbotina, E.A. Khrapov, A.

610 V. Sokolov, I.S. Stilidi, N.E. Kushlinskii, The Level of LINE-1 mRNA	V. Sokolov, I.S. Stilidi, N.E. Kushlinskii, The Level of I	LINE-1 mRNA Is
--	--	----------------

- 611 Increased in Extracellular Circulating Plasma RNA in Patients with
- 612 Colorectal Cancer, Bull. Exp. Biol. Med. 173 (2022) 261–264.
- 613 https://doi.org/10.1007/S10517-022-05530-2/METRICS.
- 614 [21] S. Sato, M. Gillette, P.R. de Santiago, E. Kuhn, M. Burgess, K. Doucette, Y. Feng,
- 615 C. Mendez-Dorantes, P.J. Ippoliti, S. Hobday, M.A. Mitchell, K. Doberstein, S.M.
- Gysler, M.S. Hirsch, L. Schwartz, M.J. Birrer, S.J. Skates, K.H. Burns, S.A. Carr,
- 617 R. Drapkin, LINE-1 ORF1p as a candidate biomarker in high grade serous
- 618 ovarian carcinoma, Sci. Rep. 13 (2023). https://doi.org/10.1038/s41598-
- 619 023-28840-5.
- 620 [22] M.S. Taylor, C. Wu, P.C. Fridy, S.J. Zhang, Y. Senussi, J.C. Wolters, T. Cajuso, W.-
- 621 C. Cheng, J.D. Heaps, B.D. Miller, K. Mori, L. Cohen, H. Jiang, K.R. Molloy, B.T.
- 622 Chait, M.G. Goggins, I. Bhan, J.W. Franses, X. Yang, M.-E. Taplin, X. Wang, D.C.
- 623 Christiani, B.E. Johnson, M. Meyerson, R. Uppaluri, A.M. Egloff, E.N. Denault,
- 624 L.M. Spring, T.-L. Wang, I.-M. Shih, J.E. Fairman, E. Jung, K.S. Arora, O.H.
- 625 Yilmaz, S. Cohen, T. Sharova, G. Chi, B.L. Norden, Y. Song, L.T. Nieman, L.
- 626 Pappas, A.R. Parikh, M.R. Strickland, R.B. Corcoran, T. Mustelin, G. Eng, O.H.
- 627 Yilmaz, U.A. Matulonis, S.J. Skates, B.R. Rueda, R. Drapkin, S.J. Klempner, V.
- 628 Deshpande, D.T. Ting, M.P. Rout, J. LaCava, D.R. Walt, K.H. Burns,
- 629 Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-
- 630 cancer biomarker, Cancer Discov. 13 (2023) 0F1–0F16.
- 631 https://doi.org/10.1158/2159-8290.CD-23-
- 632 0313/729035/AM/ULTRASENSITIVE-DETECTION-OF-CIRCULATING-LINE-
- 633

1.

634 [23] J.K. Baillie, M.W. Barnett, K.R. Upton, D.J. Gerhardt, T.A. Richmond, F. De

- 635 Sapio, P.M. Brennan, P. Rizzu, S. Smith, M. Fell, R.T. Talbot, S. Gustincich, T.C.
- 636 Freeman, J.S. Mattick, D.A. Hume, P. Heutink, P. Carninci, J.A. Jeddeloh, G.J.
- 637 Faulkner, Somatic retrotransposition alters the genetic landscape of the
- 638 human brain, Nature 479 (2011) 534–537.
- 639 https://doi.org/10.1038/nature10531.
- 640 [24] C. Chu, R. Borges-Monroy, V. V. Viswanadham, S. Lee, H. Li, E.A. Lee, P.J. Park,
- 641 Comprehensive identification of transposable element insertions using
- 642 multiple sequencing technologies, Nat. Commun. 12 (2021).
- 643 https://doi.org/10.1038/s41467-021-24041-8.
- 644 [25] E.J. Gardner, V.K. Lam, D.N. Harris, N.T. Chuang, E.C. Scott, W. Stephen
- 645 Pittard, R.E. Mills, S.E. Devine, The mobile element locator tool (MELT):
- 646 Population-scale mobile element discovery and biology, Genome Res. 27
- 647 (2017) 1916–1929. https://doi.org/10.1101/GR.218032.116/-/DC1.
- 648 [26] D.T. jwa. Thung, J. de Ligt, L.E.M. Vissers, M. Steehouwer, M. Kroon, P. de
- 649 Vries, E.P. Slagboom, K. Ye, J.A. Veltman, J.Y. Hehir-Kwa, Mobster: accurate
- detection of mobile element insertions in next generation sequencing data,
- 651 Genome Biol. 15 (2014) 488. https://doi.org/10.1186/S13059-014-0488-
- 652 X/FIGURES/3.
- 653 [27] W. Zhou, S.B. Emery, D.A. Flasch, Y. Wang, K.Y. Kwan, J.M. Kidd, J. V. Moran,
- 654 R.E. Mills, Identification and characterization of occult human-specific LINE-
- 1 insertions using long-read sequencing technology, Nucleic Acids Res. 48
- 656 (2020) 1146–1163. https://doi.org/10.1093/NAR/GKZ1173.
- 657 [28] A.C. Katz-Summercorn, S. Jammula, A. Frangou, I. Peneva, M. O'Donovan, M.
- Tripathi, S. Malhotra, M. di Pietro, S. Abbas, G. Devonshire, W. Januszewicz, A.
- Blasko, K. Nowicki-Osuch, S. MacRae, A. Northrop, A.M. Redmond, D.C.

- 660 Wedge, R.C. Fitzgerald, Multi-omic cross-sectional cohort study of pre-
- 661 malignant Barrett's esophagus reveals early structural variation and
- 662 retrotransposon activity, Nat. Commun. 13 (2022).
- 663 https://doi.org/10.1038/s41467-022-28237-4.
- 664 [29] A.W. Caliri, A. Caceres, S. Tommasi, A. Besaratinia, Hypomethylation of LINE-
- 665 1 repeat elements and global loss of DNA hydroxymethylation in vapers and
- 666 smokers, Epigenetics 15 (2020) 816–829.
- 667 https://doi.org/10.1080/15592294.2020.1724401.
- 668 [30] H. Shigaki, Y. Baba, M. Watanabe, S. Iwagami, K. Miyake, T. Ishimoto, M.
- 669 Iwatsuki, H. Baba, LINE-1 hypomethylation in noncancerous esophageal
- 670 mucosae is associated with smoking history, Ann. Surg. Oncol. 19 (2012)

671 4238-4243. https://doi.org/10.1245/s10434-012-2488-y.

- 672 [31] P. Vineis, M. Alavanja, P. Buffler, E. Fontham, S. Franceschi, Y.T. Gao, P.C.
- 673 Gupta, A. Hackshaw, E. Matos, J. Samet, F. Sitas, J. Smith, L. Stayner, K. Straif,
- M.J. Thun, H.E. Wichmann, A.H. Wu, D. Zaridze, R. Peto, R. Doll, Tobacco and
- 675 cancer: recent epidemiological evidence, J. Natl. Cancer Inst. 96 (2004) 99–
- 676 106. https://doi.org/10.1093/JNCI/DJH014.
- 677 [32] K. Hur, P. Cejas, J. Feliu, J. Moreno-Rubio, E. Burgos, C.R. Boland, A. Goel,
- 678 Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to
- activation of proto-oncogenes in human colorectal cancer metastasis, Gut 63

680 (2014) 635–646. https://doi.org/10.1136/GUTJNL-2012-304219.

- 681 [33] M. Casarotto, V. Lupato, G. Giurato, R. Guerrieri, S. Sulfaro, A. Salvati, E.
- 682 D'Angelo, C. Furlan, A. Menegaldo, L. Baboci, B. Montico, I. Turturici, R.
- 683 Dolcetti, S. Romeo, V. Baggio, S. Corrado, G. Businello, M. Guido, A. Weisz, V.
- 684 Giacomarra, G. Franchin, A. Steffan, L. Sigalotti, E. Vaccher, P. Boscolo-Rizzo,

685 P.	Ierry, G. Fanetti	. E. Fratta. LINE-1 ł	nypomethylation is a	associated with poor

686 outcomes in locoregionally advanced oropharyngeal cancer, Clin.

- 687 Epigenetics 14 (2022). https://doi.org/10.1186/s13148-022-01386-5.
- 688 [34] C. Furlan, J. Polesel, L. Barzan, G. Franchin, S. Sulfaro, S. Romeo, F. Colizzi, A.
- 689 Rizzo, V. Baggio, V. Giacomarra, A.P. Dei Tos, P. Boscolo-Rizzo, E. Vaccher, R.
- 690 Dolcetti, L. Sigalotti, E. Fratta, Prognostic significance of LINE-1
- 691 hypomethylation in oropharyngeal squamous cell carcinoma, Clin.
- 692 Epigenetics 9 (2017). https://doi.org/10.1186/S13148-017-0357-
- 693 Z/FIGURES/4.

694 [35] K. Misawa, S. Yamada, M. Mima, T. Nakagawa, T. Kurokawa, A. Imai, D.

- 695 Mochizuki, D. Shinmura, T. Yamada, J. Kita, R. Ishikawa, Y. Yamaguchi, Y.
- 696 Misawa, T. Kanazawa, H. Kawasaki, H. Mineta, Long interspersed nuclear
- 697 element 1 hypomethylation has novel prognostic value and potential utility

in liquid biopsy for oral cavity cancer, Biomark. Res. 8 (2020) 1–10.

699 https://doi.org/10.1186/S40364-020-00235-Y/FIGURES/6.

- 700 [36] A. Benard, C.J.H. Van De Velde, L. Lessard, H. Putter, L. Takeshima, P.J.K.
- 701 Kuppen, D.S.B. Hoon, Epigenetic status of LINE-1 predicts clinical outcome in

702 early-stage rectal cancer, Br. J. Cancer 109 (2013) 3073–3083.

- 703 https://doi.org/10.1038/bjc.2013.654.
- 704 [37] E.J. Kim, W.C. Chung, D.B. Kim, Y.J. Kim, J.M. Lee, J.H. Jung, Y.K. Lee, Long
- interspersed nuclear element (LINE)-1 methylation level as a molecular
- marker of early gastric cancer, Dig. Liver Dis. 48 (2016) 1093–1097.
- 707 https://doi.org/10.1016/j.dld.2016.06.002.
- 708 [38] E. Sunami, M. de Maat, A. Vu, R.R. Turner, D.S.B. Hoon, LINE-1
- 709 Hypomethylation During Primary Colon Cancer Progression, PLoS One 6

710		(2011) e18884. https://doi.org/10.1371/JOURNAL.PONE.0018884.
711	[39]	J.P. Foy, C.R. Pickering, V.A. Papadimitrakopoulou, J. Jelinek, S.H. Lin, W.N.
712		William, M.J. Frederick, J. Wang, W. Lang, L. Feng, L. Zhang, E.S. Kim, Y.H. Fan,
713		W.K. Hong, A.K. El-Naggar, J.J. Lee, J.N. Myers, J.P. Issa, S.M. Lippman, L. Mao,
714		P. Saintigny, New DNA methylation markers and global DNA
715		hypomethylation are associated with oral cancer development, Cancer Prev.
716		Res. 8 (2015) 1027–1035. https://doi.org/10.1158/1940-6207.CAPR-14-
717		0179.
718	[40]	W. McKerrow, X. Wang, C. Mendez-Dorantes, P. Mita, S. Cao, M. Grivainis, L.
719		Ding, J. LaCava, K.H. Burns, J.D. Boeke, D. Fenyö, LINE-1 expression in cancer
720		correlates with p53 mutation, copy number alteration, and S phase
721		checkpoint, Proc. Natl. Acad. Sci. U. S. A. 119 (2022).
722		https://doi.org/10.1073/PNAS.2115999119/-/DCSUPPLEMENTAL.
723	[41]	B. Tiwari, A.E. Jones, C.J. Caillet, S. Das, S.K. Royer, J.M. Abrams, P53 directly
724		represses human LINE1 transposons, Genes Dev. 34 (2020) 1439–1451.
725		https://doi.org/10.1101/GAD.343186.120/-/DC1.
726	[42]	P. Mita, X. Sun, D. Fenyö, D.J. Kahler, D. Li, N. Agmon, A. Wudzinska, S.
727		Keegan, J.S. Bader, C. Yun, J.D. Boeke, BRCA1 and S phase DNA repair
728		pathways restrict LINE-1 retrotransposition in human cells, Nat. Struct. Mol.
729		Biol. 27 (2020) 179–191. https://doi.org/10.1038/S41594-020-0374-Z.
730	[43]	N. Rodić, R. Sharma, R. Sharma, J. Zampella, L. Dai, M.S. Taylor, R.H. Hruban,
731		C.A. Iacobuzio-Donahue, A. Maitra, M.S. Torbenson, M. Goggins, I.M. Shih, A.S.
732		Duffield, E.A. Montgomery, E. Gabrielson, G.J. Netto, T.L. Lotan, A.M. De
733		Marzo, W. Westra, Z.A. Binder, B.A. Orr, G.L. Gallia, C.G. Eberhart, J.D. Boeke,
734		C.R. Harris, K.H. Burns, Long interspersed element-1 protein expression is a

- hallmark of many human cancers, Am. J. Pathol. 184 (2014) 1280–1286.
- 736 https://doi.org/10.1016/j.ajpath.2014.01.007.
- 737 [44] D. Mangoni, A. Simi, P. Lau, A. Armaos, F. Ansaloni, A. Codino, D. Damiani, L.
- 738 Floreani, V. Di Carlo, D. Vozzi, F. Persichetti, C. Santoro, L. Pandolfini, G.G.
- 739 Tartaglia, R. Sanges, S. Gustincich, LINE-1 regulates cortical development by
- 740 acting as long non-coding RNAs, Nat. Commun. 14 (2023).
- 741 https://doi.org/10.1038/s41467-023-40743-7.
- 742 [45] M. Martínez-Fernández, A. Feber, M. Dueñas, C. Segovia, C. Rubio, M.
- 743 Fernandez, F. Villacampa, J. Duarte, F.F. López-Calderón, M.J. Gómez-
- Rodriguez, D. Castellano, J.L. Rodriguez-Peralto, F. De La Rosa, S. Beck, J.M.
- 745 Paramio, Analysis of the polycomb-related lncRNAs HOTAIR and ANRIL in
- bladder cancer, Clin. Epigenetics 7 (2015). https://doi.org/10.1186/s13148-
- 747 015-0141-x.
- 748 [46] C.A. Ishak, A.E. Marshall, D.T. Passos, C.R. White, J. Seung, M.J. Cecchini, S.
- 749 Ferwati, W.A. Macdonald, J. Christopher, I.D. Welch, S.M. Rubin, M.R.W.
- 750 Mann, F.A. Dick, An RB-EZH2 Complex Mediates Silencing of Repetitive DNA
- 751 Sequences, 64 (2017) 1074–1087.
- 752 https://doi.org/10.1016/j.molcel.2016.10.021.An.
- 753 [47] P. V. Angadi, J.K. Savitha, S.S. Rao, R.Y. Sivaranjini, Oral field cancerization:
- 754 Current evidence and future perspectives, Oral Maxillofac. Surg. 16 (2012)
- 755 171–180. https://doi.org/10.1007/S10006-012-0317-X/TABLES/1.
- 756 [48] I. Martincorena, A. Roshan, M. Gerstung, P. Ellis, P. Van Loo, S. McLaren, D.C.
- 757 Wedge, A. Fullam, L.B. Alexandrov, J.M. Tubio, L. Stebbings, A. Menzies, S.
- 758 Widaa, M.R. Stratton, P.H. Jones, P.J. Campbell, High burden and pervasive
- positive selection of somatic mutations in normal human skin, Science. 348

- 761 https://doi.org/10.1126/SCIENCE.AAA6806/SUPPL_FILE/AAA6806-
- 762 MARTINCORENA-SM.PDF.
- 763 [49] K. Yoshida, K.H.C. Gowers, H. Lee-Six, D.P. Chandrasekharan, T. Coorens, E.F.
- 764 Maughan, K. Beal, A. Menzies, F.R. Millar, E. Anderson, S.E. Clarke, A.
- 765 Pennycuick, R.M. Thakrar, C.R. Butler, N. Kakiuchi, T. Hirano, R.E. Hynds, M.R.
- 766 Stratton, I. Martincorena, S.M. Janes, P.J. Campbell, Tobacco smoking and
- somatic mutations in human bronchial epithelium, Nat. 2020 5787794 578
- 768 (2020) 266–272. https://doi.org/10.1038/s41586-020-1961-1.
- 769 [50] T.G. Paulson, P.C. Galipeau, K.M. Oman, C.A. Sanchez, M.K. Kuhner, L.P. Smith,
- 770 K. Hadi, M. Shah, K. Arora, J. Shelton, M. Johnson, A. Corvelo, C.C. Maley, X.
- 771 Yao, R. Sanghvi, E. Venturini, A.K. Emde, B. Hubert, M. Imielinski, N. Robine,
- 772 B.J. Reid, X. Li, Somatic whole genome dynamics of precancer in Barrett's
- esophagus reveals features associated with disease progression, Nat.

774 Commun. 13 (2022). https://doi.org/10.1038/s41467-022-29767-7.

- [51] I. Martincorena, J.C. Fowler, A. Wabik, A.R.J. Lawson, F. Abascal, M.W.J. Hall,
- A. Cagan, K. Murai, K. Mahbubani, M.R. Stratton, R.C. Fitzgerald, P.A.
- Handford, P.J. Campbell, K. Saeb-Parsy, P.H. Jones, Somatic mutant clones
- colonize the human esophagus with age, Science. 362 (2018) 911–917.
- 779 https://doi.org/10.1126/science.aau3879.
- 780 [52] A.R.J. Lawson, F. Abascal, T.H.H. Coorens, Y. Hooks, L. O'Neill, C. Latimer, K.
- Raine, M.A. Sanders, A.Y. Warren, K.T.A. Mahbubani, B. Bareham, T.M. Butler,
- 782 L.M.R. Harvey, A. Cagan, A. Menzies, L. Moore, A.J. Colquhoun, W. Turner, B.
- 783 Thomas, V. Gnanapragasam, N. Williams, D.M. Rassl, H. Vöhringer, S.
- Zumalave, J. Nangalia, J.M.C. Tubío, M. Gerstung, K. Saeb-Parsy, M.R. Stratton,

- 785 P.J. Campbell, T.J. Mitchell, I. Martincorena, Extensive heterogeneity in
- somatic mutation and selection in the human bladder, Science. 370 (2020)
- 787 75–82. https://doi.org/10.1126/science.aba8347.
- 788 [53] C.H. Nam, J. Youk, J.Y. Kim, J. Lim, J.W. Park, S.A. Oh, H.J. Lee, J.W. Park, H.
- Won, Y. Lee, S.Y. Jeong, D.S. Lee, J.W. Oh, J. Han, J. Lee, H.W. Kwon, M.J. Kim,
- 790 Y.S. Ju, Widespread somatic L1 retrotransposition in normal colorectal
- 791 epithelium, Nature 617 (2023) 540–547. https://doi.org/10.1038/s41586-
- 792 023-06046-z.
- 793 [54] M. Shademan, K. Zare, M. Zahedi, H. Mosannen Mozaffari, H. Bagheri
- 794 Hosseini, K. Ghaffarzadegan, L. Goshayeshi, H. Dehghani, Promoter
- methylation, transcription, and retrotransposition of LINE-1 in colorectal
- adenomas and adenocarcinomas, Cancer Cell Int. 20 (2020) 1–16.
- 797 https://doi.org/10.1186/S12935-020-01511-5.
- 798
- 799

800 **FIGURE LEGENDS**

801 Figure 1. RetroTest design and benchmarking. A. RetroTest design. B. 802 Scatterplot and correlation between L1 activation and orphan transductions (TD2) 803 in the International Consortium of PanCancer (PCAWG) data. The number of L1 3' 804 transductions measured L1 activation. C. Performance of RetroTest for different 805 sequencing coverages using an artificially generated GRC37/hg19 genome with a 806 total of 2,480 randomly distributed L1 transductions at 50% VAF. **D**. Performance 807 of RetroTest with respect to the VAF of L1 integrations, using the artificially 808 generated GRC37/hg19 genome with a total of 2,480 randomly distributed L1 809 transductions at different VAFs. E. Performance of TraFiC with respect of the VAF 810 of L1 integrations, using the artificially generated GRC37/hg19 genome with a 811 total of 2,480 randomly distributed L1 transductions at different VAFs. F. Venn 812 diagram of the number of L1 insertions detected by RetroTest and TraFiC in the 813 artificial genome with a VAF of 50% for L1 insertions.

814

815 Figure 2. L1 activation measured by RetroTest in the HNSCC cohort (n=96). A. 816 Quantification of L1 activation in HNSCC tumors as the number of orphan 817 transduction detected by RetroTest. B. Boxplot of L1 activation with respect to 818 early (T1-T2) and advanced (T3-T4) TNM stages. Differential activation p-value 819 was derived by the Wilcoxon test. To correct coverage-related bias, L1 activation 820 was calculated as the number of TD2 divided by its median coverage. C. Boxplot of 821 L1 activation with respect to smoking status. Differential activation p-value was derived by the Wilcoxon test. To correct coverage-related bias, L1 activation was 822 823 calculated as the number of TD2 divided by its median coverage. D. Kaplan-Meier 824 curves for overall survival with respect to L1 activation rate at T1 stage. Patients

were grouped into high (above the median) and low (below the median) L1 activation rate. Log-rank test was used to calculate the p-value. To correct coverage-related bias, L1 activation was calculated as the number of TD2 divided by its median coverage. E. Oncoplot showing the genes affected by L1 insertions and their original source elements. A total of 27 patients presented genes affected by L1 insertions from 46 different source elements.

831

832 Figure 3. Characterization of the mutational profile of HNSCC patients by 833 **WGS** (n=19). **A.** Oncoplot showing the genes harboring somatic mutations in 834 HNSCC patients. The type of mutation in each gene and the L1 activation (number of L1 insertions in each patient) is shown. **B**. Boxplot of L1 activation with respect 835 836 to TP53 mutation or wild-type status. To correct coverage-related bias, L1 837 activation was calculated as the number of TD2 divided by its median coverage. 838 Differential activation p-value was derived by the Wilcoxon test. **C**. Barplot of the 839 Pathway enrichment analysis based on the 918 genes somatically mutated genes. 840 Enrichment p-values were calculated with the Fisher exact test. **D**. Barplot of the 841 transcription factor binding enrichment analysis based on the 918 genes 842 somatically mutated genes. Enrichment p-values were calculated with the Fisher 843 exact test.

844

Figure 4. Evaluation of L1 activation in normal adjacent tissue. A. Schematic
representation of the evaluation of the field cancerization process. B. Number of L1
active elements in normal adjacent tissue of HNSCC patients (n=9), compared to L1
activation in paired tumor tissue and PBMCs as germline control from the same
patients.

850 Table 1. Baseline characteristics of the HNSCC patients and

N = 96		
Mean age (range)	67.4 (38 – 90)	
Sex		
Female	20	
Male	71	
NA	5	
TNM stage		
T1	16	
Τ2	19	
Т3	18	
T4	34	
NA	9	
Exitus		
No	50	
Yes	38	
NA	8	
Alcohol		
Drinker	61	
Non-drinker	24	
NA	11	
Smoking habits		
Smoker	64	

851 **clinicopathological results in the series**.

	Non-smoker	22	
	NA	10	
852			
853			
854			
855			
856			

Table 2. Number of HNSCC patients showing L1 activation along TNM stages.

-	TNM stage			
	T1	Τ2	Т3	T4
L1 active	10	12	17	25
L1 inactive	6	7	1	9

858

859 ADDITIONAL FILES

860	Additional file 1 (pdf): Supplementary Methods: RetroTest library and target
861	sequencing; RetroTest method in detail; RetroTest benchmarking; Whole Genome
862	Sequencing and determination of mutation profile; Gene pathway databases uses
863	for enrichment analysis
864	Additional file 2 (xls): Table S1: RetroTest benchmarking. Table S2: HNSCC
865	somatic variants. Table S3: Gene pathways affected by HNSCC somatic variants.
866	Table S4: Transcription factors binding to genes affected by HNSCC somatic
867	variants. Table S5: HNSCC NAT somatic variants
868	Additional file 3 (pdf). Figure S1. Kaplan-Meier curves for overall survival in
869	HNSCC cohort with respect to (A) L1 activation status (active vs inactive) and (B)
870	L1 activation rate (with respect to the median, being high above vs low as below
871	the median). Log-rank test was used to calculate the p-value.
872	
873	
874	
875	
876	
877	
878	
879	
880	
881	
882	
883	

FIGURES

Figure 1.




Figure 2.








Figure 3.





- -- 1




















Patient	NAT exclusive	Tumor exclusive	Tumor-normal shared	Germline	Total
HNSCC_01	0	20	0	1	21
HNSCC_02	1	95	1	0	97
HNSCC_03	1	24	0	0	25
HNSCC_04	0	100	0	0	100
HNSCC_05	0	4	0	0	4
HNSCC_06	2	1	0	0	3
HNSCC_07	0	23	0	1	24
HNSCC_08	0	3	0	2	5
HNSCC_09	0	2	0	1	3